This trial is conducted in Europe. The aim of this trial is to investigate the exposure of NN5401 (insulin degludec/insulin aspart) in young adults and elderly subjects with type 1 diabetes mellitus.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
28
Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
Novo Nordisk Investigational Site
Graz, Austria
Area under the Glucose Infusion Rate curve (only for NN5401)
Time frame: from 0 to 24 hours after single-dose administration
Area under the glucose infusion rate curve (only for biphasic insulin aspart 30)
Time frame: from 0 to 24 hours after single-dose administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.